AU6086399A — Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2000-04-17 · 26y expired
What this patent protects
The present invention relates to new substituted indolinones of general formulawhereinX and R1 to R5 are defined as in claim 1, the isomers and the salts thereof which have valuable properties.The above compounds of general formula I wherein R1 denotes a hydrogen atom, a C1-3-alk…
USPTO Abstract
The present invention relates to new substituted indolinones of general formulawhereinX and R1 to R5 are defined as in claim 1, the isomers and the salts thereof which have valuable properties.The above compounds of general formula I wherein R1 denotes a hydrogen atom, a C1-3-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R1 does not represent a hydrogen atom, a C1-3-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.